Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Published:2017-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Angevin Eric,Bauer Todd M.,Ellis Catherine E.,Gan Hui,Hall Rigel,Hansen Aaron,Hoos Axel,Jewell Roxanne C.,Katz Jessica,Martin-Liberal Juan,Maio Michele,Mayes Patrick A.,Mazumdar Jolly,Millward Michael,Rischin Danny,Schellens Jan H.,Yadavilli Sapna,Zhou Helen

Publisher

American Association for Cancer Research

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosome miR‐27a‐3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma;Thoracic Cancer;2020-03-25

2. Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?;Frontiers in Oncology;2020-03-12

3. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future;Frontiers in Oncology;2020-01-24

4. The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review;European Journal of Cancer;2019-08

5. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy;Cancer Immunology, Immunotherapy;2018-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP